Turning a drug discovery into patient impact means choosing the right development path and knowing when to pivot. But how do you choose the best route for your drug?
Join Johnson & Johnson’s upcoming program as they bring together experts who have successfully traveled these paths and are ready to share insights into various development routes. Topics include academic-industry partnerships, IP strategies, spin-off creation, funding, and more. Don’t miss your chance to gain clarity on the pros and cons of different paths for your scientific breakthrough. Secure your place today to join fellow forward-thinking innovators in Utrecht this 3 June.
Start-ups, early innovators and entrepreneurs are welcome to register. We also welcome stakeholders supporting these start-ups.
Program
13:00 – Arrival
Visitor registration opens
For in-person attendees
13:30 – General introduction
Tess Korthout, Early Innovation Partner Benelux, Johnson & Johnson
13:45 – Current state of biotech
Wieteke Wouters, Program Director, Hollandbio*
14:05 – Next steps after discovery
Short presentations + panel discussion & Q&A
Nettie Buitelaar, CEO, Biotech Booster
Jeroen Blokhuis, Head of Valorisation, Oncode Institute
Trudy Straetemans, Lead DARE-NL & Associate Professor Translational Tumor Immunology, UMC Utrecht*
Elmer Maurits, CEO/Co-Founder, iProtics
Paul Korte, Director External Affairs, Johnson & Johnson & Board Member, FAST (moderator)
15:15 – Break
15:45 – Next steps for start-ups
Short presentations + panel discussion & Q&A
Jan-Jaap Verhoef, Founder, Imuno Therapeutics
Lilian Alcaraz, VP Early Innovation Partnering EMEA, Johnson & Johnson
Margien Boels, Investment Manager, FIRST fund, BioGeneration Ventures
Non-dilutive funding expert (to be announced)
Nettie Buitelaar, CEO, Biotech Booster (moderator)
16:55 – Closing remarks
17:00 – Informal Q&A
18:00 – End of program
*) Final confirmation pending
Source: Johnson&Johnson